Language: the WTO, with the foreign-funded pharmaceutical enterprises large-scale entry originally small, scattered, awakening and abuse of Chinese pharmaceutical industry has come a decade running. dances with Wolves, touched on how Chinese medicine enterprises? compared to foreign investment, our pharmaceutical research and innovation there is a bottleneck to breakthrough? "Medicine WTO" ten years, China medicine market leapt to global third, China for foreign drug enterprises provides has market, and originally innovation ability insufficient of local enterprise also in foreign evolution of boom in the awakening. ten years running, new drug research and development innovation, and improve drug quality, do was and dramatic. but and large transnational drug enterprises compared to, in industry concentrated of and innovation ability aspects, still anterior long. Beijing Branch Hing biological products limited now is global famous of biological medicine company, because China first support hepatitis a fight live vaccine, and World's first SARS vaccine is the company developed. and it was the first joining who under the International Federation of pharmaceutical manufacturers association
Chinese company sth Ten years ago, and constantly develop new drug challenges enough to make the process of foreign-funded pharmaceutical enterprises kexing holdings Chairman and CEO Yin Weidong proud: Yin Weidong: 1995, 1996 or so, can only watch Chinese mothers choose foreign hepatitis a vaccine for the children, and now because Chinese vaccine innovation, Chinese Pharmacopoeia standards, foreign basic delisting of hepatitis a vaccine because of quality problems. After China joins the WTO, article I of the Government's commitment in the field of medicine is to protect pharmaceutical intellectual property rights. China is a generic drug before powers, stuck a undoubtedly a lot of Chinese pharmaceutical enterprises of the neck. in order to survive, forced to engage in drug discovery and development of Chinese enterprises. Beijing kexing apparently is just a microcosm. China pharmaceutical industry association, Vice President of the Pan Guangcheng told reporters with a smile, independent innovation and research and development of new drugs against the WTO, "Wolf" the most important weapon, but the "dancing with Wolves" industries was the most important result of regulation
Fan. Pan Guangcheng: drug registration, State food and Drug Administration received the State places some of the previously registered for, making the register more standardized, more in line with international standards and practices. in terms of drug production, us and international practice, constantly refining our GMP standards for us to improve product quality, our products to international has a big role in promoting. "Dancing with Wolves" another significant achievement is that international cooperation and Exchange are becoming increasingly active. in 2001, France Shi Weiya pharmaceutical research and development centers in China, this is the first multinational companies establishing in China international pharmaceutical research and development centers. 10 years afterwards, such as Eli Lilly, Roche, Pfizer, nuohua more than more than 20 world leading multinationals are building a research and development bases in China. Xi Qing, head of Corporate Communications Department of Pfizer China briefing, research and Development Center in China's first important due to the Chinese market, second is optimistic about China's talent.
Xi Qing: talent is also a very important piece. in addition, China requires that even if your drug in Europe has done clinical, to enter China, but also to do clinical, early clinical in China if you synchronize, registered in China listed will accelerate in the future. Zhuo Yongqing is China foreign investment Association drug development and Development Committee President, he with "you in the has I, I in the has you" to evaluation transnational drug enterprises giant in China established research and development base this a phenomenon: Zhuo Yongqing: in China established of these research and Development Center most employees are is Chinese, course this inside has in Europe transnational pharmaceutical work had of Chinese, also has many of talent is we China of college training out of, also has expert. they are participate in to new drug of research and development system inside. Transnational pharmaceutical with domestic of academics, and Industry has been gradually formed "you have in me, and I have you" eco-system. "You have in me, and I have you"
The sound development of foreign trade has been the rapid development of Chinese medicine, in 2001, China pharmaceutical foreign trade only amounted to us $ 9.5 billion in 2010, this figure had reached $ 60.2 billion, more than 10 years ago increased 5 times times. market participants expect Chinese became the world's third-largest pharmaceutical market in 2011, with an average annual growth exceeding 25%, market size of more than 50 billion dollars. WTO ten years, China of medicine market capacity and contribution of are has living in world forefront, China is became global medicine industry growth of important engine. but WTO ten years, why we also no formed group of has international competitiveness of enterprise? China drug enterprises and international giant of gap what in where? continues to to listening to reporter of reported: China chemical pharmaceutical industrial Association Vice, President of Pan Guangcheng feeling said, ten years Qian we see medicine industry, regardless of is industrial, and commercial, also is retail, with four a word evaluation, is small, and bulk, and abuse, and Low. ten years after this
Days we describe this industry, is still the four words: small, scattered, abuse, low. in 2001, through the national drug administration supervision in our country Enterprise 5,446 households, by September 2010, the pharmaceutical enterprises of pharmaceutical industry still there were 4,707. Pan Guangcheng: Qian 100 strong of enterprise now of yield only accounted for to domestic of 33% around, with China of conditions has relationship--too large, although (drug enterprises) small, but products also has must of market, so enterprise also has survival of space, but as Twelve-Five planning implementation yihou, also is increased merger, and joint recombinant process, target is Qian 100 strong of enterprise can accounted for to domestic production of 60%. Pharmaceutical research and development of long cycle, into huge risks enormous, in order to encourage the drug discovery and development, starting in 2008, China has embarked on a major new drug created special. Twelve-Five "period, Central xiabo 10 billion yuan Special Fund and another $ 30 billion of matching funds, and strive to self-
No comments:
Post a Comment